Replies to post #3191 on Synergy Pharmaceuticals Inc fka SGYPQ

[Opti Mist]

I hear you, Al. Bios are dangerous stocks. The science is exciting, but so often the business end appears to be as cluttered as a messy office. Good science and good drug development do not always translate to good company to invest in. This one has its head in the sand when it comes to caring for its stockholders. Eventually it will be sold for $2 per share if that.

Too big a mess to recover.

JMHO

opti

[Infominer777]

I posted this earlier. Maybe this is what the Gambler is referring to.

https://www.smarteranalyst.com/2018/01/25/synergy-pharmaceuticals-inc-management-attributes-todays-stock-weakness-investor-uncertainty-companys-cash-balance/

Key paragraph in the above article from SGYP management,

“With two approved indications, they believe Trulance will become increasingly competitive in the commercial market. Essential to the ability to access the next tranche of cash ($100 million) from the existing loan agreement is a cash balance of $128 million as of January 31. For legal reasons, management indicated that they could not provide an update until that time. Expressing confidence they will meet that obligation, we believe actual disclosure of that fact could be a positive catalyst for the stock,” the analyst continued.